H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rockwell Medical to $11 from $9 and keeps a Buy rating on the shares. The company’s acquisition of the hemodialysis concentrates business from privately-held Evoqua Water Technologies is immediately accretive and poised to boost revenue, the analyst tells investors in a research note. The firm says the transaction should broaden Rockwell’s geographic reach in the U.S. and increase revenue in an immediately accretive manner. It says Rockwell is poised to become the leading supplier of liquid bicarbonate products to U.S. dialysis centers upon the closing of this transaction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RMTI:
- Rockwell Medical raises 2023 revenue view to $82M-$86M from $78M-$82M
- Rockwell Medical acquires hemodialysis concentrates business from Evoqua Water
- Rockwell Medical announces 3-year co-promotional pact with B. Braun Medical
- Windtree Therapeutics appoints Strobeck to board of directors
- Rockwell Medical added to Russell Microcap Index